Prot# M02-516: A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Project: Research project

Project Details

StatusFinished
Effective start/end date2/10/04 → 2/9/09

Funding

  • Paragon Biomedical, Inc. (M02-516 // M02-516)
  • Abbott Laboratories (M02-516 // M02-516)